“The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.”
All entries for: Multiple
August 3, 2023
IGM Biosciences
Negative Outlook
Mountain View, CA
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 12, 2023
IGM Biosciences
Negative Outlook
Mountain View, CA
201-500 employees
201-500 employees
“The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.”
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 10, 2023
Pfizer
Neutral Outlook
New York, NY
50,001+ employees
50001+ employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 8, 2023
Zymeworks
Negative Outlook
Middletown, DE
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology, Therapeutics
Drug Type: Biologic
May 8, 2023
Recursion Pharmaceuticals
Neutral Outlook
Salt Lake City, UT
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 4, 2023
Alnylam
Negative Outlook
Cambridge, MA
1,001-5,000 employees
1001-5000 employees
Disease Area: Multiple
Drug Type: Biologic
May 4, 2023
Regeneron
Neutral Outlook
Tarrytown, NY
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
April 27, 2023
Eli Lilly & Company
Negative Outlook
Indianapolis, IN
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic
January 20, 2023
Novartis
Negative Outlook
Basel, Switzerland
50,001+ employees
50001+ employees
“U.S. government plans to rein in drug prices could discourage work in some of Novartis’s most promising areas of research, the Swiss drugmaker warned on Friday, urging Washington to rethink the “unintended” effects of its new rules… Lawmakers’ intention may be to favour sophisticated biologics over seemingly more conventional chemical drugs, but some of the most promising new treatment approaches belong to the latter group, said Victor Bulto, Novartis’s President Innovative Medicines for the U.S. market. “The most concerning piece in that legislation for us is the price setting after nine years for small molecules and 13 years for biologics,” Bulto told Reuters.”
Disease Area: Multiple, Oncology
Drug Type: Small Molecule
November 8, 2022
Zymeworks
Negative Outlook
Middletown, DE
201-500 employees
201-500 employees
Concerns over Revenue Generation: “The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcarereforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved”
Disease Area: Multiple, Oncology, Therapeutics
Drug Type: Biologic